Research brief: Antibody drug to protect pancreas in diabetics

A trial to test whether the monoclonal antibody rituximab can preserve pancreas function in type-1 diabetes is to begin in April, researchers from Indiana University in the US have announced. The researchers believe rituximab could also save pancreatic function in patients with type-1 diabetes because it attacks B lymphocytes thought to prime T cells to attack the pancreas.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in